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ABSTRACT: Major adverse cardiovascular events are closely associated with 24-hour blood pressure (BP). We determined
outcome-driven thresholds for 24-hour mean arterial pressure (MAP), a BP index estimated by oscillometric devices. We
assessed the association of major adverse cardiovascular events with 24-hour MAP, systolic BP (SBP), and diastolic BP
(DBP) in a population-based cohort (n=11 596). Statistics included multivariable Cox regression and the generalized R2
statistic to test model fit. Baseline office and 24-hour MAP averaged 97.4 and 90.4 mm Hg. Over 13.6 years (median),
2034 major adverse cardiovascular events occurred. Twenty-four-hour MAP levels of <90 (normotension, n=6183), 90 to
<92 (elevated MAP, n=909), 92 to <96 (stage-1 hypertension, n=1544), and ≥96 (stage-2 hypertension, n=2960) mm Hg
yielded equivalent 10-year major adverse cardiovascular events risks as office MAP categorized using 2017 American
thresholds for office SBP and DBP. Compared with 24-hour MAP normotension, hazard ratios were 0.96 (95% CI, 0.80–
1.16), 1.32 (1.15–1.51), and 1.77 (1.59–1.97), for elevated and stage-1 and stage-2 hypertensive MAP. On top of 24-hour
MAP, higher 24-hour SBP increased, whereas higher 24-hour DBP attenuated risk (P<0.001). Considering the 24-hour
measurements, R2 statistics were similar for SBP (1.34) and MAP (1.28), lower for DBP than for MAP (0.47), and reduced
to null, if the base model included SBP and DBP; if the ambulatory BP indexes were dichotomized according to the 2017
American guideline and the proposed 92 mm Hg for MAP, the R2 values were 0.71, 0.89, 0.32, and 0.10, respectively. In
conclusion, the clinical application of 24-hour MAP thresholds in conjunction with SBP and DBP refines risk estimates.
(Hypertension. 2021;77:39–48. DOI: 10.1161/HYPERTENSIONAHA.120.14929.) Data Supplement

•
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T

he Global Burden of Disease Study 2010 reported
that high blood pressure (BP) is the major modifiable cardiovascular risk factor, causing 9.4 million
deaths annually, that is, more than half of cardiovascular mortality.1 Prevention of the cardiovascular complications associated with hypertension requires that
BP be accurately measured,2 preferably by 24-hour

ambulatory monitoring.3,4 Because mercury is being
phased out, oscillometry is replacing the auscultatory
Korotkoff approach in use since 1910.5 The proprietary software implemented in automated oscillometric
devices draws an envelope around the pressure oscillations in the brachial cuff and estimates mean arterial
pressure (MAP) as the cuff pressure at the point of
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Novelty and Significance
What Is New?
• We established in a population-based cohort of 11 596
adult people outcome-driven thresholds for 24-hour
mean arterial pressure (MAP), and we assessed its
associations with fatal and nonfatal cardiovascular end
points.

1 hypertension, and stage 2 combined with severe
hypertension, respectively.
• Combined with 24-hour systolic BP and diastolic BP,
24-hour MAP kept its prognostic accuracy in categorical and continuous analyses of BP.

Summary
What Is Relevant?
• Using a composite cardiovascular end point as primary
outcome and the 10-year risks associated with 2017
American College of Cardiology/American Heart
Association thresholds for office blood pressure (BP)
as reference, we established levels of 24-hour MAP of
<90, ≥90 to <92, ≥92 to <96, and ≥96 mm Hg delineated normotension, elevated 24-hour MAP, stage

Nonstandard Abbreviations and Acronyms
BP
DBP
MAP
SBP

blood pressure
diastolic BP
mean arterial pressure
systolic BP
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maximal oscillations (Figure S1 in the Data Supplement). From the so estimated MAP, the software then
computes systolic and diastolic BP.6,7 For validated
devices, the fault tolerance around the calculated systolic and diastolic BP is ±5 mm Hg.8 Furthermore, MAP
is similar throughout the arterial tree,9 thereby avoiding
the dilemma as to whether central compared with brachial BP confers higher cardiovascular risk.10 In addition, MAP captures risk-related information associated
with both systolic and diastolic BP.11 In an individual
participant meta-analysis of 1 million people, office
MAP was a better predictor of vascular mortality than
systolic or diastolic BP or pulse pressure.12 However,
to our knowledge, hypertension guidelines do not
propose how MAP should be used for risk stratification.3,4 We recently demonstrated that of all in-office
and ambulatory BP indexes the association of mortality
and cardiovascular complications was closest with the
24-hour ambulatory BP.13 Given the clinical underuse
of MAP and the predictive superiority of 24-hour BP,13
we established in a population-based cohort of 11 596
adults, recruited in Europe, Asia, and South America,
outcome-driven thresholds for 24-hour MAP that might
guide clinical practice and we assessed the strength of
its associations with fatal and nonfatal cardiovascular
end points.
40   January 2021

Our observations have implications for hypertension
management and the use and validation of oscillometric BP measuring devices. Oscillometric BP measuring
devices should include MAP in the reports they generate. Considering 24-hour MAP in clinical practice in
conjunction with 24-hour systolic BP and diastolic BP
might refine risk estimates.

METHODS
The International Database on Ambulatory Blood Pressure in
Relation to Cardiovascular Outcome data and the SAS programs written for the present analysis will not be made available to other researchers because participant-level data sharing
was not covered by the informed consent and because this
option is not in compliance with the General Data Protection
Act (EU Directive 2016/680). However, any scientifically
motivated request, submitted to the study coordinator (J.A.
Staessen), to run additional analyses on the data set used in
the current article, will be implemented if only summary statistics are requested.

Study Participants
All population studies included in the International Database
on Ambulatory Blood Pressure in Relation to Cardiovascular
Outcome13,14 received ethical approval from the Institutional
Review Boards in their country of origin and adhered to the
principles of the Declaration of Helsinki.15 Participants provided informed written consent. The International Database
on Ambulatory Blood Pressure in Relation to Cardiovascular
Outcome database, constructed and maintained in Leuven,
did not include any data allowing identification of individuals.
In line with national regulations, Review Boards either waived
or provided ethical clearance for the secondary use of data to
be included in the International Database on Ambulatory Blood
Pressure in Relation to Cardiovascular Outcome resource.
Population studies qualified for inclusion, if office and ambulatory BP and cardiovascular risk factors had been measured at
baseline and if follow-up included both fatal and nonfatal outcomes. Across all studies, enrollment took place from August
1985 until May 2010 (Table S1). Baseline refers to the date
of the first BP measurement, ranging across cohorts from May
1985 until May 2010; the last follow-up data were collected
from August 2007 to October 2016. Table S2 provides the literature sources describing the design characteristics of the 13
studies (references 1–25 in the Data Supplement).
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Nurses or physicians measured office BP with a standard
mercury sphygmomanometer or with validated auscultatory or
oscillometric devices. The office BP was the average of 2 consecutive readings. MAP on office measurement was diastolic
BP plus one-third of pulse pressure (the difference between
systolic and diastolic BP) and categorized according to the
2017 American guidelines for systolic and diastolic pressure,3
rounded to the closest integer. The cut off points were <93
mm Hg for normotension ([80+0.33]×[120–80]) mm Hg; 93 to
<97 mm Hg for elevated BP; 97 to <107 mm Hg for stage-1
hypertension, ≥107 mm Hg for stage-2 hypertension combined
with severe hypertension. Hypertension was an office BP of
≥130 mm Hg systolic or ≥80 mm Hg diastolic or use of antihypertensive drugs.3
For ambulatory monitoring (Table S3), portable oscillometric
monitors were programmed to obtain readings at 30-minute
intervals throughout the whole day or at intervals of 15 to 30
minutes during daytime and at intervals ranging from 20 to 60
minutes during nighttime. Ambulatory recordings had to include
at least 6 daytime and 3 nighttime readings.16

Ascertainment of End Points

Downloaded from http://ahajournals.org by on December 10, 2020

We ascertained vital status and the incidence of fatal and
nonfatal end points from the appropriate sources in each
country. Prespecified end points were coded according to
the International Classification of Diseases (Table S4). The
primary end point was a composite cardiovascular outcome
consisting of cardiovascular mortality, including sudden
death, nonfatal coronary events, coronary revascularization,
heart failure, and stroke. Secondary end points included
total mortality, cardiovascular mortality, fatal and nonfatal
coronary end points, and fatal and nonfatal stroke excluding transient ischemic attack. The diagnosis of heart failure required hospitalization in the 2 Scandinavian cohorts
(Table S4). In the other cohorts, it was a clinical diagnosis or the diagnosis on the death certificate. All end points
were validated against hospital files or medical records held
by primary care physicians, specialists, or hospitals. In all
outcome analyses, only the first event within each category
was considered. Participants free of events were censored
at last follow-up.

Statistical Analysis
For database management and statistical analysis, we used
SAS software, version 9.4, maintenance level 5. We applied
the Kolmogorov-Smirnov test for assessing the normality of
distributions. For between-group comparison of means and
proportions, we applied the large-sample z-test and Fisher
exact test, respectively. After stratification for cohort and
sex, we interpolated missing values of body mass index and
total serum cholesterol from the regression slopes on age. In
participants with unknown status of smoking, drinking, diabetes, or history of cardiovascular disease, we set the indicator (dummy) variable to the cohort- and sex-specific mean of
the codes (0, 1).
In multivariable-adjusted Cox regression, we accounted
for cohort (random effect), sex, and baseline characteristics including age, body mass index, smoking and drinking,

serum cholesterol, antihypertensive drug intake, history of
cardiovascular disease, and diabetes. To adjust for cohort,
we pooled participants recruited in the framework of the
European Project on Genes in Hypertension (Gdańsk,
Kraków, Novosibirsk, Padova, and Pilsen; Table S1). We
checked the proportional hazards assumption by the
Kolmogorov-type supremum test and by testing the interaction between BP and follow-up time.
We obtained operational thresholds for MAP by ambulatory monitoring in 5 steps.14 First, we computed the 10-year
incidence rates of end points associated with office MAP,
using as thresholds 93, 97, and 107 mm Hg. Second, we computed the 10-year risk of end points associated with ambulatory MAP ranging from the 10th up to the 90th percentile,
using intervals of 2 mm Hg. In a third step, we selected the
ambulatory MAP levels that were associated with similar
10-year risks as the office MAP thresholds. Next, we calculated the bootstrap distribution of the so obtained ambulatory
MAP thresholds by randomly resampling the study population
1000× with replacement. For each new sample, we repeated
the first 3 steps, while accounting for tied event times. Finally,
we calculated the bootstrap point estimates and 95% CIs of
the ambulatory MAP thresholds as the mean±1.96 SEs of the
bootstrap distribution.
Based on the thresholds for the 24-hour MAP obtained by
the bootstrap procedure, we computed incidence rates and
multivariable-adjusted hazard ratios as metrics of absolute and
relative risk, respectively. Rates were standardized by the direct
method for cohort, sex and age (<40, 40 to <60, and ≥60
years) and 95% CIs were computed as R ± 1.96 × (R/N),
where R and N are the rate and the number of individuals used
to compute the rate. We constructed heat maps to visualize the
contribution of 24-hour systolic, diastolic, and 24-hour MAP to
the association with the primary end point. Improvement in the
fit of nested Cox models was assessed by the log likelihood
ratio and the generalized R2 statistic.17 Statistical significance
was a 2-tailed α-level of 0.05 or less.

RESULTS
Baseline Characteristics
Of 13 728 people included in the database, we excluded
2132, because they were adolescents younger than 18
years (n=317), because their office BP or use of antihypertensive drugs had not been recorded at baseline
(n=255), or because their ambulatory BP recording
included fewer readings than required (n=1560). This
left 11 596 individuals for statistical analysis (Table 1).
Missing values of body mass index (n=34), serum cholesterol (n=903), smoking (n=96), diabetes (n=5), and
history of cardiovascular disease (n=1) were interpolated
or set to the cohort- and sex-specific means. Table 1 lists
the baseline characteristics of the participants. Mean age
at enrollment was 52.8 years. Across increasing fourths
(quartiles) of the 24-hour MAP distribution (Table S5),
the percentage of women decreased while the prevalence of hypertension and diabetes increased as well as
the average levels of office and 24-hour BP, body mass
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Statistic (n=11 596)

mm Hg (Table 1). All BP measurements were highly correlated (Table S6; P<0.0001).

Women, n (%)

5754 (49.6)

24-Hour MAP Thresholds

Europeans, n (%)

7096 (61.2)

Asians, n (%)

2181 (18.8)

South Americans, n (%)

2319 (20.0)

Current smoking, n (%)*†

3150 (27.2)

Drinking alcohol, n (%)*‡

6006 (51.8)

Office hypertension, n (%)§∥

7424 (64.1)

In all Cox regression models that follow, the proportional
hazard assumption was met. The number of person-years
of follow-up totaled 158 431 in 11 596 participants. Over a
median follow-up of 13.6 years (5th–95th percentile interval, 3.6–26.0), 2034 primary end points occurred, including 916 (45.0%) coronary end points, and 809 (39.8%)
strokes. Over the same time span, 2821 participants died,
1059 (37.5%) of cardiovascular disease (Table S4). Using
the bootstrap procedure (Table 2), we obtained as thresholds for 24-hour MAP: <90 mm Hg (normotension); 90 to
<92 mm Hg (elevated MAP); 92 to <96 mm Hg (stage-1
hypertension), and ≥96 mm Hg (stage-2 combined with
severe hypertension; henceforth referred to as stage-2
hypertension). The corresponding thresholds for daytime
and nighttime MAP were 94/80 mm Hg, 96/82 mm Hg,
and 104/88 mm Hg for elevated, stage 1 and stage 2
hypertension, respectively. The thresholds based on the
full data set were similar to the means of the bootstraps.
In sensitivity analyses, rounded thresholds were 2 mm Hg
lower in women than in men, and among participants with
a previous history of cardiovascular diseases (Table S7).
However, the thresholds remained largely consistent using
16/6 or 11/5 for the number of daytime/nighttime readings, in participants untreated or treated for hypertension
at baseline, in patients with or without diabetes at baseline (Table S7), after excluding one cohort at a time (Table
S8), and in Europeans compared with Asians and South
Americans (Table S9).

Table 1. Baseline Characteristics of Participants
Characteristics
Participants with characteristics

   On antihypertensive treatment, n (%)*

2273 (19.6)

Diabetes, n (%)¶

885 (7.6)

History of cardiovascular disease, n (%)*

1287 (11.1)

Mean (±SD) of characteristics
Age, y

52.8±15.9

Body mass index, kg/m2#

25.4±4.4

Office systolic blood pressure, mm Hg∥

132.6±23.4

Office diastolic blood pressure, mm Hg∥

79.8±12.1

Office mean arterial pressure, mm Hg∥

97.4±14.5

Twenty-four hour systolic blood pressure, mm Hg**

123.6±14.4

Twenty-four hour diastolic blood pressure, mm Hg**

73.9±8.7

Twenty-four hour mean arterial pressure, mm Hg**

90.4±8.2

Twenty-four hour heart rate, beats per minute

72.5±9.2

Serum cholesterol, mg/dL††

212.8±43.7

Blood glucose, mg/dL††

94.3±26.4

Downloaded from http://ahajournals.org by on December 10, 2020

*Assessed by questionnaire or interview at baseline.
†Use of smoking materials on a daily basis.
‡Occasional or daily consumption of alcoholic beverages.
§An office blood pressure of ≥130 mm Hg systolic or ≥80 mm Hg diastolic, or
use of antihypertensive drugs.
∥Office blood pressure was measured using mercury sphygmomanometers or
validated auscultatory or oscillometric devices. Mean arterial pressure was diastolic blood pressure plus one-third of pulse pressure (the difference between
systolic and diastolic blood pressure).
¶Use of antidiabetic drugs, fasting blood glucose of ≥126 mg/dL (7.0
mmol/L), random blood glucose of ≥200 mg/dL (11.1 mmol/L), a self-reported
diagnosis, or diabetes documented in practice or hospital records.
#Body weight in kilogram divided by body height in meters squared.
**Twenty-four hour blood pressure was measured with validated oscillometric
devices (see Table S3 in the Data Supplement).
††Serum cholesterol and blood glucose were measured by automated methods in certified laboratories. Conversion factors: to convert cholesterol to mmol/L,
multiply by 0.0259; to convert glucose to mmol/L, multiply by 0.056.

index, serum cholesterol, and blood glucose (P value for
linear trend <0.001).

Office and Ambulatory BP
On office measurement, systolic/diastolic BP averaged
132.6/79.8 mm Hg, and MAP 97.4 mm Hg (Table 1). The
median number of ambulatory readings recorded over
24-hour was 55 (5th–95th percentile interval, 33–82),
ranging across cohorts (Table S3) from 37 (5th–95th
percentile interval, 26–42) to 80 (5th–95th percentile
interval, 67–83). On 24-hour monitoring, systolic/diastolic BP averaged 123.6/73.9 mm Hg, and MAP 90.4
42   January 2021

Absolute Risk Associated With 24-Hour MAP
Based on the aforementioned MAP thresholds, the
primary end point occurred in 715 of 6183 normotensive participants (11.6%; rate per 1000 person-years,
11.9 [95% CI, 11.1–13.2]); in 134 of 909 people with
elevated BP (14.7%; 11.3 [9.5–13.6]); in 312 of 1544
participants with stage-1 hypertension (20.2%; 15.2
[13.5–17.2]); and in 873 of 2960 stage-2 hypertensive
patients (29.5%; 21.5 [20.0–23.3]). The increase in
absolute risk across higher MAP categories was highly
significant (P<0.001). This was also the case for the
secondary end points (Table S10).

Relative Risk Associated With 24-Hour MAP
Compared with the normotensive reference group
(Table 3), the relative risk of a primary end point associated with 24-hour MAP was 32% higher in patients
with stage-1 hypertension and 77% higher in those
with stage-2 hypertension (P<0.001). For the secondary end points, the corresponding risk estimates ranged
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End points

Reference office MAP* thresholds and associated 10-y risk†

Ambulatory MAP* thresholds yielding equivalent 10-y risk
Point estimate (95% CI)†

Proposed threshold‡

Type

No.

Level,
mm Hg

Risk in percent
(95% CI)

24 h

Daytime

Nighttime

24 h

NightDaytime time

All cardiovascular end points

2034

93

4.55 (4.09–5.00)

89.4 (88.5–90.3)

93.4 (92.2–94.6)

79.3 (78.1–80.5)

90

94

Total mortality

2821

Cardiovascular
mortality

1059

Coronary end
points

916

Stroke

809

80

97

4.81 (4.35–5.27)

91.5 (90.9–92.0)

96.1 (95.5–96.8)

81.7 (80.9–82.4)

92

96

82

107

5.54 (5.04–6.04)

96.6 (95.9–97.3)

103.1 (102.1–104.1)

87.6 (86.7–88.4)

96

104

88

93

3.75 (3.38–4.12)

89.4 (87.9–90.8)

92.7 (89.9–95.4)

80.2 (78.8–81.6)

90

92

80

97

3.86 (3.49–4.24)

91.5 (90.7–92.3)

96.0 (94.6–97.3)

82.1 (81.3–82.9)

92

96

82

107

4.17 (3.76–4.59)

96.7 (95.5–97.9)

104.1 (101.7–106.6)

86.9 (85.7–88.2)

96

104

86

93

1.12 (0.91–1.33)

90.4 (88.9–91.9)

94.2 (91.9–96.5)

80.7 (79.0–82.5)

90

94

80

97

1.18 (0.96–1.40)

92.4 (91.4–93.4)

96.9 (95.4–98.5)

82.9 (81.7–84.1)

92

96

82

107

1.36 (1.11–1.62)

97.3 (96.4–98.3)

103.8 (102.6–105)

88.2 (87.1–89.3)

96

104

88

93

2.17 (1.84–2.49)

89.3 (87.5–91.1)

93.3 (90.7–95.8)

79.7 (77.6–81.8)

90

94

80

97

2.25 (1.92–2.57)

91.1 (90.2–91.9)

95.7 (94.5–96.9)

81.6 (80.5–82.7)

92

96

82

107

2.45 (2.09–2.81)

95.5 (93.9–97.2)

101.7 (99.4–104.1)

86.4 (84.6–88.3)

96

102

86

93

1.71 (1.45–1.97)

89.5 (88.2–90.8)

93.5 (91.9–95.1)

79.2 (77.6–80.8)

90

94

80

97

1.85 (1.57–2.13)

91.7 (90.9–92.5)

96.4 (95.5–97.3)

81.8 (80.7–82.8)

92

96

82

107

2.26 (1.92–2.61)

97.3 (96.5–98.1)

103.8 (102.7–104.9)

88.3 (87.3–89.2)

96

104

88
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MAP indicates mean arterial pressure.
*MAP was estimated from office blood pressure (MAP=diastolic blood pressure plus one-third of the difference between systolic and diastolic blood pressure) or
estimated using oscillometric ambulatory monitors. Oscillometric devices compute systolic and diastolic blood pressure, using proprietary algorithms (Figure S1 in the
Data Supplement).
†The ambulatory MAP thresholds were computed by bootstrapping 1000× multivariable-adjusted Cox models.
‡Proposed thresholds were obtained by rounding the point estimates to the closest even integer value, except for the risk of cardiovascular mortality and stroke events
associated with 24-h MAP stage 2 combined with severe hypertension, which were set at 96 mm Hg instead of 98 mm Hg for reasons of consistency and precaution.

from 16% to 52% for stage-1 hypertension (P≤0.173 to
<0.010) and from 39% to 90% for stage-2 hypertension
(P<0.001). These findings were direction wise consistent in 6996 participants younger than 60 years and in
4600 patients aged 60 years or more (Table 3), albeit
that in the younger age group the relative risk of cardiovascular mortality and coronary end points was formally
significant only in patients with stage-2 hypertension
(P<0.001). The interaction terms between age and the
24-hour MAP categories were nonsignificant (Table 3).

Association of the Primary End point With MAP,
Systolic and Diastolic BP
We stratified the analysis of 24-hour MAP by the median
of the MAP distribution (90 mm Hg). In 2-mm Hg steps,
hazard ratios were computed for lower and higher MAP
levels with as reference group participants with levels
of 90 mm Hg or more or <90 mm Hg, respectively. In
line with the data in Table 2, the risk of the primary end
point (Figure 1A) increased above unity at a level of ≈92
mm Hg. Using the American College of Cardiology/American Heart Association thresholds for 24-hour systolic/
diastolic BP (<125/<75 versus ≥125/≥75 mm Hg) and
the presently obtained thresholds for 24-hour MAP (<92
versus ≥92 mm Hg; Table 2), the 11 596 participants
were subdivided in 4 groups. For systolic combined with

MAP, 6284 people (54.2%) were normotensive for both
BP indexes (group A), 808 (7.0%) had high systolic BP
but normal MAP (group B), 585 (5.0%) had normal systolic BP but elevated MAP (group C), and 3919 (33.8%)
had both elevated systolic BP and MAP (group D). For
cross-classification with diastolic BP, these numbers
were 6427 (55.4%), 665 (5.7%), 518 (4.5%), and 3986
(34.4%), respectively. In multivariable-adjusted analyses
with group A as reference, the relative risk was similar in
systolic/diastolic groups B (+8%/−8%; P≥0.317; Figure 1B and 1C) but elevated in group C (+34%/+46%;
P≤0.027) and in group D (+71%/+64%; P<0.001).
Heat maps combining 24-hour systolic, diastolic and
MAP (Figure 2) showed along the horizontal axis that
the 10-year risks of the primary end point increased with
higher MAP (P<0.001). Along the vertical axis, higher
systolic BP (Figure 2C; P<0.001) added to the risk conferred by MAP, whereas higher diastolic BP attenuated
the risk (Figure 2D; P<0.001). Combined with MAP,
24-hour pulse pressure added to the risk conferred
by MAP (Figure S2), replicating the results for systolic
BP (Figure 2C). Finally, we assessed the log likelihood
ratios and generalized R2 statistics across nested models. The associations of the primary end point with MAP
and systolic BP, both analyzed as continuous variables,
were similar if the base model included the covariables
accounted for in adjusted analyses (R2, 1.34 and 1.28,
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Table 2. Ambulatory MAP Thresholds Yielding Equivalent 10-y Risk Compared With the Reference Thresholds of Office MAP
in 11 596 Participants
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Table 3. Association of End Points With 24-h Mean Arterial Pressure Categories
End points category of
mean arterial pressure

All ages N=11 596
E/AR*

HR† (95% CI)†

<60 y N=6996
P value

E/AR*

HR (95% CI)†‡

≥60 y N=4600
P value

E/AR*

HR (95% CI)†‡

P value

Primary end point
Normotension

715/6183

153/4308

562/1875

Elevated

134/909

0.96 (0.80–1.16)

0.674

28/537

1.25 (0.83–1.89)

0.282

106/372

0.89 (0.72–1.10)

0.266

Stage-1 hypertension

312/1544

1.32 (1.15–1.51)

<0.001

52/799

1.36 (0.98–1.88)

0.067

260/745

1.29 (1.11–1.50)

0.001

Stage-2 and severe
hypertension

873/2960

1.77 (1.59–1.97)

<0.001

152/1352

2.14 (1.67–2.75)

<0.001

721/1608

1.69 (1.50–1.90)

<0.001

Secondary end points
Total mortality
Normotension

1107/6183

199/4308

908/1875

Elevated

215/909

0.99 (0.85–1.15)

0.883

35/537

1.24 (0.86–1.78)

0.259

180/372

0.95 (0.81–1.12)

0.542

Stage-1 hypertension

450/1544

1.17 (1.05–1.31)

0.005

65/799

1.25 (0.93–1.67)

0.137

385/745

1.16 (1.03–1.31)

0.016

Stage-2 and severe
hypertension

1049/2960

1.39 (1.27–1.53)

<0.001

144/1352

1.80 (1.42–2.28)

<0.001

905/1608

1.34 (1.21–1.47)

<0.001

Cardiovascular mortality
Normotension

358/6183

Elevated

62/909

0.85 (0.65–1.12)

0.248

7/537

45/4308
1.04 (0.46–2.33)

0.932

55/372

313/1875
0.83 (0.62–1.11)

0.203

Stage-1 hypertension

165/1544

1.31 (1.09–1.59)

0.005

16/799

1.32 (0.73–2.38)

0.358

149/745

1.31 (1.08–1.60)

0.007

Stage-2 and severe
hypertension

474/2960

1.84 (1.59–2.13)

<0.001

53/1352

2.53 (1.63–3.93)

<0.001

421/1608

1.77 (1.52–2.07)

<0.001

1.00 (0.76–1.32)

0.978

18/537

1.47 (0.86–2.50)

0.155

46/372

0.88 (0.64–1.22)

0.445

Coronary end points
Normotension

322/6183

Elevated

64/909

80/4308

242/1875
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Stage-1 hypertension

132/1544

1.16 (0.94–1.42)

0.173

29/799

1.32 (0.85–2.05)

0.213

103/745

1.12 (0.88–1.41)

0.360

Stage-2 hypertension

398/2960

1.58 (1.35–1.86)

<0.001

87/1352

2.22 (1.58–3.12)

<0.001

311/1608

1.44 (1.20–1.72)

<0.001

Stroke
Normotension

278/6183

Elevated

41/909

0.74 (0.53–1.03)

0.076

7/537

57/4308
0.87 (0.39–1.93)

0.734

34/372

221/1875
0.71 (0.50–1.03)

0.070

Stage-1 hypertension

135/1544

1.52 (1.23–1.88)

<0.001

24/799

1.90 (1.16–3.14)

0.012

111/745

1.43 (1.14–1.81)

0.002

Stage-2 and severe
hypertension

355/2960

1.90 (1.60–2.24)

<0.001

43/1352

1.67 (1.07–2.59)

0.023

312/1608

1.93 (1.61–2.32)

<0.001

BP indicates blood pressure; and HR, hazard ratio.
*E/AR denotes the number of end points/number of participants at risk.
†HR, given with 95% CI describe the relative risk compared with normotensive participants. HRs were adjusted for cohort (random effect), sex, and baseline characteristics including age, body mass index, smoking and drinking, serum cholesterol, antihypertensive drug intake, history of cardiovascular disease, and diabetes.
‡The interaction terms between age and BP category were nonsignificant, except for stage-2 and severe hypertension among subjects <60 y (P<0.03).

respectively; Table S11). For MAP added to the covariables and diastolic BP, the R2 was 0.47. If the base model
included the covariables and both systolic and diastolic
BP, continuous MAP did not add to the model fit (Table
S11). If MAP and systolic and diastolic BP were dichotomized as in Figure 1B, the corresponding R2 values were
0.71, 0.89 0.32, and 0.10, respectively (Table S12).

DISCUSSION
Using a composite cardiovascular end point as primary
outcome, statistical methods published before,14 and
the 10-year risks associated with the 2017 ACC/AHA
thresholds for office BP as reference,3 we computed
thresholds for 24-hour MAP. We focused on 24-hour
44   January 2021

ambulatory BP derived thresholds because we recently
demonstrated that of all in-office and ambulatory BP
indexes, mortality and fatal combined with nonfatal cardiovascular end points were closely associated with the
24-hour BP level.13 Levels of 24-hour MAP of <90, 90
to <92, 92 to<96, and ≥96 mm Hg delineated normotension, elevated 24-hour MAP, stage-1 hypertension,
and stage-2 combined with severe hypertension, respectively. With higher 24-hour MAP categories, both the
absolute and relative risks of adverse events increased,
as captured by the incidence and hazard ratios, respectively. These observations withstood multiple sensitivity
analyses and held true for the primary and secondary
end points. Combined with 24-hour systolic and diastolic
BP, 24-hour MAP kept its prognostic accuracy in categorical and continuous analyses of BP.

Hypertension. 2021;77:39–48. DOI: 10.1161/HYPERTENSIONAHA.120.14929

Melgarejo et al

The fit of the associations of the primary end point
with MAP and systolic BP, both analyzed as continuous
variables, were similar if the base model included only

the covariables accounted for in adjusted analyses, but
if the base model also included systolic and diastolic BP,
continuous MAP did no longer add to the model fit (Table
S11). These observations are in line with the concept that
diastolic BP is the main determinant of MAP and that
MAP captures information related to both systolic and
diastolic BP. If the BP indexes were dichotomized, using
the ACC/AHA thresholds for systolic (125 mm Hg) and
diastolic (75 mm Hg) BP and the outcome-driven MAP
threshold derived in this article (92 mm Hg), MAP did
add to a model including covariables and both systolic
and diastolic BP thresholds. The log likelihood ratios and
generalized R2 statistics only evaluate model fit but not
the strength of the association of an end point with a BP
index, as shown in Figure 2. As demonstrated by numerous placebo and actively controlled trials18 and long-term
cohort studies of populations13 and patients,19 BP is the
overriding modifiable cardiovascular risk factor. Small
increments in R2 challenge this concept. However, major
irreversible risk factors, such as sex and age, on their own
already generate an R2 of 23.94%. Consequently, adding
BP to multivariable-adjusted models that already account
for sex, age, and other risk factors cannot substantially
augment R2. Under such conditions, many researchers
share the opinion that markers of model fit are imprecise
and that clinical relevance is of greater importance than
the improvement of the model fit.20
From a physiological point of view, BP and blood flow
can be broken down into a pulsatile component with systolic and diastolic BP representing the extremes of the
BP oscillations around MAP, which drives organ perfusion.21 When peripheral resistance increases by rarefaction or remodeling of arterioles, MAP rises with parallel
increments in systolic and diastolic BP. However, when
there is an additional reduction of arterial compliance, as
occurs with stiffening of the large arteries, both systolic
BP and MAP increase¸ whereas diastolic BP decreases.22
Figure 2 illustrates these concepts, showing that the
10-year risk of the primary end point was consistently
greater with higher MAP with an additional contribution
of systolic BP, whereas higher diastolic BP attenuated
the risk. Diastolic BP is within 2 mm Hg similar throughout the arterial system.9 Pulse pressure is the difference
between systolic and diastolic BP. These hemodynamic
principles explain why adding systolic BP (Figure 2C) or
pulse pressure (Figure S2), which both reflect the pulsatile component of BP, produced similar results.
The clinical relevance of our study pertains to the consideration of MAP for identifying hypertension and categorizing individuals according to their risk for adverse
health outcomes. As reported before,1,23 relative risk was
higher at young than older age, whereas absolute followed the opposite trend (Table 3). Our observations
have implications for hypertension management and the
use and validation of oscillometric BP measuring devices.
Treatment wise, targeting lower systolic BP goals24 is
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Figure 1. Multivariable-adjusted hazard ratios (HRs; 95% CI) for
the primary end point in relation to 24-h blood pressure (BP).
A, The analysis was stratified by the median (90 mm Hg) of mean
arterial pressure (MAP). HRs were computed comparing participants
with MAP ≤80, ≤82, ≤84, ≤86, or ≤88 with those with MAP >90
mm Hg and comparing participants with MAP ≥92, ≥94, ≥96, ≥98,
≥100, or ≥102 with those with MAP <90 mm Hg. Hazard ratios were
adjusted for cohort (random effect), sex, and baseline characteristics
including age, body mass index, smoking and drinking, serum
cholesterol, antihypertensive drug intake, history of cardiovascular
disease, and diabetes. Vertical bars denote 95% CIs. This plot
confirmed the increase in risk when MAP was ≥92 mm Hg. B and C,
The 11 596 participants were subdivided according the American
College of Cardiology/American Heart Association thresholds for
24-h systolic BP (SBP) and diastolic BP (DBP) and the calculated
24-h MAP thresholds (Table 2). The multivariable-adjusted HRs,
given with 95% CI, represent the risk of a primary end point with
normotension for SBP and MAP (B) or normotension for diastolic
and MAP (C) as reference. E/AR indicates number of participants
with a primary end point/number of participants at risk; and NT/HT,
normotension/hypertension, and E/AR number of participants with a
primary endpoint/number of participants at risk.
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Figure 2. Heat maps depicting the 10-y risk of a primary end point in relation to 24-h mean arterial, systolic and diastolic BP in
11 596 participants.
Numbers in the (A) and (B) grids represent the percentage of participants within each BP cross-classification category; numbers in (C) and (D)
represent the 10-y risks. Heat maps were derived by Cox proportional hazards regression with systolic BP (C) or diastolic BP (D) plotted along
the vertical axis and mean arterial pressure (MAP) along the horizontal axis. Estimates of the 10-y risk were standardized to the average of the
distributions in the whole study population (mean or ratio) of all covariables. Higher MAP consistently conferred greater risk (P<0.001) with an
additional contribution of systolic BP (P<0.001 [C]), whereas higher diastolic BP attenuated the risk (P<0.001 [D]).

likely to reduce risk, but only when MAP and diastolic
BP are not lowered below levels required for the perfusion of the cerebrovascular,25 coronary,26 and renal24 vascular beds. Oscillometric BP measuring devices should
include MAP in the reports they generate, as this information might carry clinical information.

Strengths and Limitations
Generalizability is among the strengths of our study. Participants were randomly recruited from populations in 12
countries and 3 continents. End points were collected
46   January 2021

over a median of 13.6 years of follow-up and encompassed both fatal and nonfatal events all adjudicated
against the source documents available in each country.
Notwithstanding these strengths, our study must also be
interpreted within the context of its possible limitations.
Asians and South Americans were under-represented. We
had no information on Black people of African descent or
Black people born and living in Africa, who generally are
more susceptible to the complications of hypertension.27
Our findings were obtained in participants aged 18 years
without upper age limit. They are obviously not applicable
in children and young adolescents. Finally, we assessed
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Perspectives
When using oscillometric devices for 24-hour BP monitoring, <90, 90 to <92, 92 to<96, and ≥96 mm Hg are the
outcome-driven thresholds for 24-hour MAP, delineating
normotension, elevated BP and stage-1, and stage-2
combined with severe hypertension. Adopting 24-hour
MAP in clinical practice in conjunction with 24-hour systolic and diastolic BP might refine risk estimates (Figure 2) and increase awareness that overtreatment of BP
potentially confers risk, if the perfusion pressure of vital
organs is lowered too much.24–26
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